Navigation Links
Ease-of-Use and Intuitive Nature of the DATATRAK eClinical(TM) Platform Allows for Further Operational Efficiencies

Closure of German office and consolidation of Help Desk services results in approximately $1.1 million of annualized expense reduction and increases

Company competitiveness

CLEVELAND, June 17 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced as part of its ongoing efforts to maximize operational efficiencies, the Company will be closing its Bonn, Germany office. Throughout the past year the German office of DATATRAK was mainly providing global Help Desk services in support of the Company's two existing electronic platforms for clinical trials. Help Desk services will now be provided through the Company's headquarters based in Cleveland and will continue to service the global implementations of DATATRAK's products. These initiatives when fully implemented will result in annual costs savings of approximately $1.1 million.

DATATRAK's previous product offering of EDC-only was originally acquired from the German Division of Electronic Data Systems in 1998. This legacy product necessitated more intense supervision and support which translated into a higher cost requirement. The newer DATATRAK eClinical platform is far more user-friendly, modern and intuitive which results in a diminished requirement for support, allowing for a consolidation of these services within a lower cost environment. All of the new clinical trials being implemented by DATATRAK exclusively use the new platform, while the older EDC-only product suite is planned to have its few remaining trials concluded by late 2009 or early 2010.

"Everyone who has ever been associated with the DATATRAK family expresses the highest level of sincerity and respect for the German operation that has provided exemplary service to our worldwide customers and users for the past ten years," stated Dr. Jeffrey A. Green, President and Chief Executive Officer of DATATRAK International, Inc. "This office of DATATRAK was the early pioneer in this industry during the 1990s. However, the advancing innovative nature of our platform is directed towards as much self-reliance as possible for our customers and users and this fact combined with the economic disadvantages of the currency exchange rates necessitated this sound business decision. In the end, this action will increase our corporate competitiveness which will translate into additional advantages for our clients through the use of the DATATRAK eClinical platform."

About DATATRAK International

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. The DATATRAK eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer ASP model that fully empowers clients to design, set up and manage their clinical trials independently. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 separate drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA." Visit the DATATRAK International, Inc. web site at

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Wolters Kluwer Health Introduces Formulary Facts(TM), a Formulary Analytics Tool that Sets the Standard for Accuracy and Ease-of-Use
2. Arthritis Foundation Grants Ease-Of-Use Commendation to Duracell EasyTab Hearing Aid Battery
3. ACCU-CHEK(R) Aviva System Receives Arthritis Foundations Ease-of-Use Commendation
4. Cardica, Intuitive Surgical, MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium
5. Xceed Molecular Licenses Signature from Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
6. Natures Cure Acne Products Land Coveted Expert Endorsement of Michael Maddox
7. Answers From Nature Introduces 100% Non-China Ingredients for Dietary Supplements
8. Jefferson, Ohio State team find gene signature profile for metastasis
9. Sonoma Developer Oakmount Senior Living Marries Architecture With Nature to Recreate Tuscany at Varenna
10. After Collecting 22 Million Petition Signatures on, Bipartisan Breast Cancer Patient Protection Act Gets First Congressional Hearing in 12 Years
11. Determining genetic signature of lung tumors can help guide treatment
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology: